News of Note—Flu vaccines, CureVac and more

newspaper
In this week's news of note, InvVax reported positive preclinical results for a universal flu vaccine candidate. (Pixabay)

Here is some other vaccine news of note for the week:

> About 37% of U.S. adults got a flu vaccine last year, according to the CDC. The figure represented about a 6% decline from the prior year. MarketWatch article

> CureVac started a phase 1 study of a mRNA-based rabies vaccine candidate. Release

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

> ImmusanT kicked off a phase 2 study of its Nexvax2 in patients with celiac disease. Release

> A report found that low vaccine confidence in Europe is contributing to a higher number of disease outbreaks. Reuters article

> Privately held biotech InvVax touted preclinical results for its universal flu vaccine candidate. Release